The anti-obesity drugs market was valued at USD 4.60 Billion in 2025, driven by rising prevalence of obesity across the 8 major markets. The market is expected to grow at a CAGR of 43.72% during the forecast period of 2026-2035, with the values likely to reach USD 172.95 Billion by 2035.
Base Year
Historical Period
Forecast Period
In January 2024, Omega Therapeutics, Inc., and Novo Nordisk announced a research collaboration to develop novel therapeutics for obesity management. Surge in research initiatives to manage rising obesity rates is a major market trend.
In January 2024, EraCal Therapeutics and Novo Nordisk announced a collaboration and license agreement to develop and commercialize the EraCal’s oral, small molecule program intended to treat obesity. Under the terms of agreement, Novo Nordisk obtains the exclusive rights to develop and commercialize the program, while EraCal is entitled to get an upfront, development and commercial milestone payments of up to EUR 235 million along with the further royalties on sales.
In January 2024, Rhythm Pharmaceuticals, Inc., entered into a licensing agreement with LG Chem, Ltd. for LG54640, an investigational Phase-II oral small molecule melanocortin-4 receptor (MC4R) indicated to treat obesity.
Compound Annual Growth Rate
43.72%
Value in USD Billion
2026-2035
*this image is indicative*
Anti-obesity drugs target different aspects of weight management such as appetite suppression, fat absorption, and metabolic enhancement. There are several anti-obesity drugs approved by the United States Food and Drug Administration (FDA) for long-term use, including Bupropion-naltrexone (Contrave), Liraglutide (Saxenda), Orlistat (Xenical, Alli), Phentermine-topiramate (Qsymia), and Semaglutide (Wegovy), among others. Some weight loss medications like semaglutide (Wegovy), liraglutide (Saxenda), and tirzepatide (Zepbound) can help in reducing body weight by 20%.
The anti-obesity drugs market growth is driven by the rising prevalence of obesity worldwide, increasing awareness about the health risks associated with obesity, and growing partnerships in obesity-related research. For instance, in February 2024, Obesity Canada partnered with My Viva Inc., in order to support people living with obesity. “My Viva Plan” created by My Viva is the lifestyle management tool useful for creating personalized fitness planning. Moreover, to raise the awareness among the individuals, International Obesity Collaborative (IOC), a global initiative aimed at addressing the obesity on international scale was also formed. The IOC comprised of 12 international organizations including the obesity medicine association. Furthermore, the surge in drug approvals by health regulatory agencies and innovation in drug development are some of the factors that are expected to positively influence the market landscape.
Rising Prevalence of Obesity to Foster the Market Landscape Significantly
The market is driven by rising prevalence of obesity which makes an individual prone to various health complications such as diabetes, cardiovascular diseases, and certain cancers. According to the World Health Organization (WHO), in 2022, around 2.5 billion adults (18 years or older) were overweight, out of which around 890 million adults were living with obesity. This equates to about 43% of the adults being overweight which shows an increase from the 1990, when 25% of adults aged 18 years and above were overweight. In addition, as per the latest World Obesity Atlas 2023, it is expected that the number of individuals falling in the overweight and obesity category will reach 4 billion by 2035. This indicates that every 1 in 5 women and 1 in 7 men, will be living with obesity by 2030.
Increased Strategic Merger and Initiatives to Meet Rising Anti-Obesity Drugs Market Demand
One of the significant market trends is the rise in strategic merger and acquisition initiatives taken by the key market players to expand production capacities and support the development of novel drug pipelines. Recently, in January 2024, Roche completed the acquisition of Carmot Therapeutics Inc. dedicated in developing the therapeutics for the people living with metabolic diseases including obesity and diabetes. Further, rising investments aimed at introducing safer and more efficient anti-obesity drugs in the market are also anticipated to accelerate market growth. In January 2024, Adipo Therapeutics closed a USD 1.9 million seed financing gap to advance the treatment of Type 2 diabetes and obesity.
The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:
"Global Anti-Obesity Drugs Market Report and Forecast 2026-2035" offers a detailed analysis of the market based on the following segments:
Breakup by Drug Type
Breakup by Drug Class
Breakup by Mechanism of Action
Breakup by Prescription Type
Breakup by Distribution Channel
Breakup by Region
Market Segmentation Based on Product Type is Anticipated to Witness Substantial Growth
By drugs, the market is segmented into Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide, Gelesis 100, Orlistat, Phentermine, Methamphetamine, and Tirzepatide. Each anti-obesity drug works on distinct mechanisms and shows different effects on weight management. Among the different anti-obesity drugs, the two anti-obesity drugs that have been approved for long-term usage are sibutramine and orlistat. However, they can even cause minor side-effects such as flatulence and diarrhea.
Based on region, United States is the market is witnessing significant growth which can attributed to an advanced healthcare system offering access to various anti-obesity drugs to the huge patient population. With 78% of adults in the United States estimated to be overweight or obese by 2030, the rising prevalence of obesity in the region is poised to propel the market growth in the coming years. In addition, the increased funding, and investments to support the development of novel weight loss drugs is expected to augment the anti-obesity drugs market demand.
Europe also holds a high market value, owing to the presence of leading market players in the region. Moreover, the dominance of the regional market is a result of the rising adoption of obesity treatment solutions and growing investments in obesity research and drug development. India is projected to witness substantial growth. It can be accredited to changing lifestyle of the people that can result in obesity.
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Established over 100 years ago, Novo Nordisk is a Danish pharmaceutical company that boasts a well-established anti-obesity drugs portfolio, including Wegovy and amycretin. Wegovy is a prescription based injectable while amycretin is an oral pill that works by stimulating gut hormones and controls blood sugar levels along with appetite.
United States based Eli Lilly and Company spans across 18 countries. It has 2 major anti-obesity drugs including Mounjaro and Zepbound. Zepbound™ (tirzepatide) intended for chronic weight management received FDA approval in November 2023. The company has also initiated phase three clinical trials for a novel oral weight-loss drug called orforglipron in India.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other major market players include Rhythm Pharmaceuticals, KVK Tech Inc., Currax Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Vivus LLC, Gelesis Holding Inc., GlaxoSmithKline PLC, Pfizer Inc., and Boehringer Ingelheim International GmbH.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Upto 15% Off
USD
$3299 $2969
$5499 $4949
$6999 $5949
$8199 $6969
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Drug Class |
|
| Breakup by Mechanism of Action |
|
| Breakup by Prescription Type |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share